All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest update on the SEQUOIA trial of zanubrutinib + venetoclax in treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL
Listen to the podcast here:
SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL
In this interview, Paolo Ghia shares preliminary outcomes from Arm D of the phase III SEQUOIA (NCT03336333) study of patients with del(17p) and/or pathogenic TP53 mutation, treated with zanubrutinib in combination with venetoclax. Ghia covers key data, highlighting promising remission rates and an increased depth of response measured over time. This interview concludes with a look to the future implications of these data, particularly on measurable residual disease-guided treatment cessation.
During the interview, Ghia made the following key points1:
This educational resource is independently supported by BeiGene. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox